{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:37:20Z","timestamp":1787686640339,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.clinthera.2010.02.004","type":"journal-article","created":{"date-parts":[[2010,3,8]],"date-time":"2010-03-08T02:38:57Z","timestamp":1268015937000},"page":"300-310","source":"Crossref","is-referenced-by-count":74,"title":["Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy"],"prefix":"10.1016","volume":"32","author":[{"given":"Giovanni","family":"Corrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Merlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.02.004_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.02.004_bib2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(96)04292-4","article-title":"West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.02.004_bib3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.02.004_bib4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AF-CAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.02.004_bib5","doi-asserted-by":"crossref","first-page":"3i","DOI":"10.1016\/S0002-9149(03)00503-4","article-title":"The Heart Protection Study: Expanding the boundaries for high-risk coronary disease prevention","volume":"92","author":"Farmer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib6","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.02.004_bib7","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomized controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2010.02.004_bib8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2010.02.004_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1524-4733.2005.00052.x","article-title":"Patterns and effectiveness of lipid-lowering therapies in a managed care environment","volume":"8","author":"Meyer","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2010.02.004_bib10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.amjcard.2006.08.063","article-title":"Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice","volume":"99","author":"Kamal-Bahl","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.clinthera.2005.10.005","article-title":"Compliance with a statin treatment in a usual care setting: Retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia","volume":"27","author":"Caspard","year":"2005","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2010.02.004_bib12","first-page":"306","article-title":"Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population","volume":"11","author":"Schultz","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2010.02.004_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2125.2005.02478.x","article-title":"Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997\u20132003","volume":"60","author":"Walley","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.02.004_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.02.004_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-009-0673-0","article-title":"Impact of better adherence to statin agents in the primary prevention of coronary artery disease","volume":"65","author":"Perreault","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib17","first-page":"117","article-title":"Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy","volume":"2","author":"Corrao","year":"2008","journal-title":"BioMed Stat Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00228-007-0428-8","article-title":"Adherence to statin therapy and patients' cardiovascular risk: A pharmacoepidemiological study in Italy","volume":"64","author":"Poluzzi","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib20","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.clinthera.2008.12.003","article-title":"Long-term persistence with statin therapy: A nationwide register study in Finland","volume":"30","author":"Helin-Salmivaara","year":"2008","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2010.02.004_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.02.004_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.90.1.583","article-title":"Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents","volume":"90","author":"Tunstall-Pedoe","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2010.02.004_bib23","series-title":"Analysing Survival Data from Clinical Trials and Observational Studies","author":"Marubini","year":"1995"},{"key":"10.1016\/j.clinthera.2010.02.004_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib25","series-title":"Epidemiology: Study Design and Data Analysis","author":"Woodward","year":"2005"},{"key":"10.1016\/j.clinthera.2010.02.004_bib26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2125.2005.02355.x","article-title":"Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention","volume":"59","author":"Perreault","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib27","first-page":"388","article-title":"Adherence with statins over 8 years in a usual care setting","volume":"14","author":"Vinker","year":"2008","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.clinthera.2010.02.004_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/14740330802396984","article-title":"Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality","volume":"7","author":"Liberopoulos","year":"2008","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.clinthera.2010.02.004_bib29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archinternmed.2008.552","article-title":"Continuation of statin treatment and all-cause mortality. A population-based cohort study","volume":"169","author":"Shalev","year":"2009","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2010.02.004_bib30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.02.004_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.02.004_bib32","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. PRO-spective Study of Pravastatin in the Elderly at Risk","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.02.004_bib33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: Results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1503\/cmaj.1041403","article-title":"Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: An evaluation of class effect","volume":"172","author":"Zhou","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2010.02.004_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6904-9-6","article-title":"Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people","volume":"9","year":"2009","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib36","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.02.004_bib37","series-title":"Pharmacoepidemiology","first-page":"219","article-title":"Overview of automated databases in pharmacoepidemiology","author":"Strom","year":"2000"},{"key":"10.1016\/j.clinthera.2010.02.004_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2125.2007.03066.x","article-title":"\u2018Real-life\u2019 reduction in cholesterol with statins, 1993 to 2002","volume":"65","author":"Murphy","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.maturitas.2007.03.001","article-title":"Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes","volume":"57","author":"Corrao","year":"2007","journal-title":"Maturitas"},{"key":"10.1016\/j.clinthera.2010.02.004_bib40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/oxfordjournals.aje.a112408","article-title":"Bias due to misclassification in the estimation of relative risk","volume":"105","author":"Copeland","year":"1977","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib41","first-page":"685","article-title":"How should we measure medication adherence in clinical trials and practice?","volume":"3","author":"Lee","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2010.02.004_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: Methods, validity, and applications","volume":"50","author":"Steiner","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","article-title":"Confounding by indication: An example of variation in the use of epidemiology terminology","volume":"149","author":"Salas","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2010.02.004_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1207\/s15324796abm2702_6","article-title":"Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment","volume":"27","author":"Stilley","year":"2004","journal-title":"Ann Behav Med."},{"key":"10.1016\/j.clinthera.2010.02.004_bib45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medications","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.02.004_bib46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/pds.730","article-title":"Determinants of non-compliance with lipidlowering therapy in hyperlipidemic patients","volume":"11","author":"Kim","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.clinthera.2010.02.004_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2337\/diacare.28.3.595","article-title":"Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia","volume":"28","author":"Parris","year":"2005","journal-title":"Diabetes Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181000055X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181000055X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T14:17:43Z","timestamp":1558880263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181000055X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S014929181000055X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.02.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}